Monica H. Cerqueira

Rio De Janeiro, RJ, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Journal: Research and practice in thrombosis and haemostasis

Published: February 18, 2026

Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study.

Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: June 13, 2025

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors.

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors.

Journal: Research and practice in thrombosis and haemostasis

Published: May 12, 2025

Genomic ancestry, F8 variants, and immune tolerance in hemophilia A patients with inhibitors: exome sequencing insights.

Genomic ancestry, F8 variants, and immune tolerance in hemophilia A patients with inhibitors: exome sequencing insights.

Journal: Haematologica

Published: December 20, 2024

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.

Journal: The New England journal of medicine

Published: September 25, 2024

Longitudinal Evaluation of Immunological Biomarkers in Previously Untreated/Minimally Treated Patients With Severe and Moderately Severe Haemophilia A During Exposure to Factor VIII: Results From the HEMFIL Study.

Longitudinal Evaluation of Immunological Biomarkers in Previously Untreated/Minimally Treated Patients With Severe and Moderately Severe Haemophilia A During Exposure to Factor VIII: Results From the HEMFIL Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 23, 2024

Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.

Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.

Journal: Thrombosis research

Published: May 11, 2024

High levels of anti-factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia A and high-responding inhibitors.

High levels of anti-factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia A and high-responding inhibitors.

Journal: Research and practice in thrombosis and haemostasis

Published: March 25, 2024

Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network.

Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network.

Journal: Journal of thrombosis and haemostasis : JTH

Published: February 04, 2024

Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.

Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 13, 2022

Effect of the First Factor VIII Infusions on Immunological Biomarkers in Previously Untreated Patients with Hemophilia A from the HEMFIL Study.

Effect of the First Factor VIII Infusions on Immunological Biomarkers in Previously Untreated Patients with Hemophilia A from the HEMFIL Study.

Journal: Thrombosis and haemostasis

Published: January 10, 2021

Title Not Found

Title Not Found

Journal: Jornal vascular brasileiro

Published: June 23, 2018

Showing 1-12 of 15

Last Updated: 09/26/2026